Severe Community-acquired Pneumonia
Conditions
Brief summary
Severe community-acquired pneumonia still has a high incidence and mortality, but the molecular mechanism and prognostic biomarkers of severe community-acquired pneumonia caused by different pathogens are still unclear, and the best treatment strategy has not been determined. Based on this, this project intends to take patients with severe community-acquired pneumonia caused by different pathogens as the research object, explore the molecular mechanism of severe community-acquired pneumonia from multiple angles, integrate relevant research data to evaluate the rationality of initial empirical medication, and lay the foundation for precise treatment of severe pneumonia. The research results will help to develop a new rapid and accurate target for clinical diagnosis and efficacy evaluation of severe pneumonia, and build a precise treatment system for severe pneumonia.
Interventions
DIAGNOSTIC_TESTMulti-omics tests
Biological sample collection for Multi-omics tests
Sponsors
Capital Medical University
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
Age\> 18 years old Clinical diagnosis of community-acquired pneumonia
Exclusion criteria
Pregnancy, perinatal and lactating women Combined immunosuppressive diseases: such as HIV, solid organ transplantation, solid organ/hematologic malignant tumor chemotherapy, rheumatic diseases or glomerular diseases need to take hormone/immunosuppressant therapy Combined blood system diseases: such as leukemia reactions, aplastic anemia, neutropenia or deficiency of granulocytes, previous bone marrow/stem cell transplantation
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Hospital mortality | during hospitalization (up to day 14) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Cause of death | during hospitalization (up to day 14) | — |
| Length of stay | during hospitalization (up to day 14) | — |
| Length of ICU stay | during hospitalization (up to day 14) | — |
| Expense during hospitalization | during hospitalization (up to day 14) | All expenses incurred in hospitalization, including bed fee, examination fee, operation or treatment fee. |
Countries
China
Contacts
Primary ContactZhaohui Tong, Dr
Outcome results
None listed